July 30, 2012
United States Securities and Exchange Commission
Jim B. Rosenberg, Senior Assistant Chief Accountant
Division of Corporation Finance
100 F Street N.E.
Washington, DC 20549
Re: | Cubist Pharmaceuticals, Inc. |
Dear Mr. Rosenberg:
We acknowledge receipt of your comment letter dated July 26, 2012, with respect to Cubist Pharmaceuticals, Inc.’s Form 10-K for the year ended December 31, 2011.
We respectfully request an extension of 11 business days in order to adequately respond to your comments, and our response would be submitted no later than August 24, 2012.
Sincerely,
/s/ David W.J. McGirr |
|
David W.J. McGirr
Senior Vice President and Chief Financial Officer
cc: | Michael W. Bonney, Chief Executive Officer |
| Tamara Joseph, Senior Vice President, General Counsel, and Secretary |